Skip to main content

Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials

Abstract

The relative efficacy and tolerability of tocilizumab, sarilumab, and sirukumab were assessed in patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX) or tumor necrosis factor (TNF) inhibitors. We performed a Bayesian network meta-analysis to combine direct and indirect evidence from randomized controlled trials (RCTs) to examine the efficacy and safety of tocilizumab, sarilumab, and sirukumab in RA patients and an inadequate MTX or TNF inhibitor response. Fourteen RCTs, comprising 9753 patients, met the inclusion criteria. Tocilizumab 8 mg combined with MTX or as monotherapy was the most effective treatment for active RA with an inadequate MTX or TNF antagonist response, followed by sarilumab and sirukumab, regardless of MTX combination. The ranking probability based on the surface under the cumulative ranking curve (SUCRA) indicated that tocilizumab 8 mg + MTX had the highest probability of being the best treatment to achieve the ACR50 response rate, followed by tocilizumab 8 mg, sarilumab 200 mg, sarilumab 200 mg + MTX, sirukumab 100 mg, tocilizumab 4 mg + MTX, sirukumab 100 mg + MTX, sirukumab 50 mg + MTX, sarilumab 150 mg + MTX, adalimumab 40 mg, and sirukumab 50 mg, and placebo + MTX. No significant differences were observed in withdrawals owing to adverse events after treatment with tocilizumab 8 mg + MTX, sirukumab 100 mg + MTX, or sarilumab 200 mg + MTX. In RA patients with an inadequate MTX or anti-TNF therapy response, tocilizumab 8 mg as monotherapy and combined with MTX showed acceptable tolerability and the highest performance based on the ACR50 response rate, followed by sarilumab and sirukumab.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2

References

  1. Felson DT, Anderson JJ, Meenan RF (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two meta-analyses. Arthritis Rheum 33(10):1449–1461. https://doi.org/10.1002/art.1780331001

    CAS  Article  PubMed  Google Scholar 

  2. Kremer JM (2004) Toward a better understanding of methotrexate. Arthritis Rheum 50(5):1370–1382. https://doi.org/10.1002/art.20278

    CAS  Article  PubMed  Google Scholar 

  3. Aletaha D, Smolen JS (2002) The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 41(12):1367–1374. https://doi.org/10.1093/rheumatology/41.12.1367

    CAS  Article  Google Scholar 

  4. Brennan FM, Maini RN, Feldmann M (1992) TNF alpha—a pivotal role in rheumatoid arthritis? Br J Rheumatol 31(5):293–298. https://doi.org/10.1093/rheumatology/31.5.293

    CAS  Article  PubMed  Google Scholar 

  5. Lipsky P, van der Heijde D, St Clair E, Furst D, Breedveld F, Kalden J, Smolen J, Weisman M, Emery P, Feldmann M (2000) Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Group. N Engl J Med 343(22):1594–1602. https://doi.org/10.1056/NEJM200011303432202

    CAS  Article  PubMed  Google Scholar 

  6. Nurnberg W, Haas N, Schadendorf D, Czarnetzki BM (1995) Interleukin-6 expression in the skin of patients with lupus erythematosus. Exp Dermatol 4(1):52–57. https://doi.org/10.1111/j.1600-0625.1995.tb00222.x

    CAS  Article  PubMed  Google Scholar 

  7. Srirangan S, Choy EH (2010) The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis 2(5):247–256. https://doi.org/10.1177/1759720X10378372

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R, Investigators O (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987–997

    CAS  Article  PubMed  Google Scholar 

  9. Genovese M, Fleischmann R, Fiore S, Radin A, Fan C, Huizinga T (2013) SAT0117 Sarilumab, a subcutaneously-administered, fully-human monoclonal antibody inhibitor of the IL-6 receptor: relationship between Eular responses and change from baseline of selected clinical parameters. Ann Rheum Dis 72:A620–A620

    Google Scholar 

  10. Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, Davis HM, Zhou H (2011) Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol 72(2):270–281. https://doi.org/10.1111/j.1365-2125.2011.03964.x

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, Kishimoto T (2009) Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 19:12–19

    CAS  Article  PubMed  Google Scholar 

  12. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, Kavanaugh A (2012) Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 71(2):198–205. https://doi.org/10.1136/ard.2010.148700

    CAS  Article  PubMed  Google Scholar 

  13. Emery P, Keystone E, Tony H, Cantagrel A, Van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516–1523

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying Antirheumatic drug therapy study. Arthritis Rheum 58:2968–2980

    CAS  Article  PubMed  Google Scholar 

  15. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J (2013) Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381(9877):1541–1550. https://doi.org/10.1016/S0140-6736(13)60250-0

    CAS  Article  PubMed  Google Scholar 

  16. Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Vargas JI, Lee EB (2016) Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Annals of the rheumatic diseases: annrheumdis-2016-210310

  17. Fleischmann R, van Adelsberg J, Lin Y, da Rocha C-PG, Brzezicki J, Hrycaj P, Graham NM, van Hoogstraten H, Bauer D, Burmester GR (2017) Sarilumab and non-biologic disease-modifying Antirheumatic drugs in patients with active RA and inadequate response or intolerance to TNF inhibitors. Arthritis Rheum 69(2):277–290. https://doi.org/10.1002/art.39944

    CAS  Article  Google Scholar 

  18. Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, Rohane P, van Hoogstraten H, Garg A, Fan C (2015) Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheum 67(6):1424–1437. https://doi.org/10.1002/art.39093

    CAS  Article  Google Scholar 

  19. Aletaha D, Bingham CO, Tanaka Y, Agarwal P, Kurrasch R, Tak PP, Popik S (2017) Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. Lancet 389(10075):1206–1217. https://doi.org/10.1016/S0140-6736(17)30401-4

    CAS  Article  PubMed  Google Scholar 

  20. Takeuchi T, Thorne C, Karpouzas G, Sheng S, Xu W, Rao R, Fei K, Hsu B, Tak PP (2017) Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Ann Rheum Dis 76(12):2001–2008. https://doi.org/10.1136/annrheumdis-2017-211328

    Article  PubMed  PubMed Central  Google Scholar 

  21. Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B (2014) Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis-2013-205137

  22. Development JR A Study of CNTO 136 (sirukumab) administered subcutaneously in Japanese patients with active rheumatoid arthritis unresponsive to methotrexate or sulfasalazine. Available from: https://clinicaltrials.gov/ct2/show/NCT01689532?term=NCT01689532&rank=1. NLM identifier: NCT01689532

  23. Janssen, Development R A study comparing sirukumab (CNTO 136) monotherapy with adalimumab (HUMIRA®) monotherapy in the treatment of active rheumatoid arthritis (SIRROUND-H). Available from: https://clinicaltrials.gov/ct2/show/NCT02019472?term=NCT02019472&rank=1. NLM identifier: NCT01604343

  24. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F (1992) The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35(5):498–502. https://doi.org/10.1002/art.1780350502

    CAS  Article  PubMed  Google Scholar 

  25. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Care Res 59(10):1371–1377. https://doi.org/10.1002/art.24123

    CAS  Article  Google Scholar 

  26. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12. https://doi.org/10.1016/0197-2456(95)00134-4

    CAS  Article  PubMed  Google Scholar 

  27. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269. https://doi.org/10.7326/0003-4819-151-4-200908180-00135

    Article  PubMed  Google Scholar 

  28. Brown S, Hutton B, Clifford T, Coyle D, Grima D, Wells G, Cameron C (2014) A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL. Syst Rev 3:110

    Article  PubMed  PubMed Central  Google Scholar 

  29. Caldwell DM, Ades A, Higgins J (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ: Br Med J 331:897

    Article  Google Scholar 

  30. Salanti G, Ades A, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163–171

    Article  PubMed  Google Scholar 

  31. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades A (2013) Evidence synthesis for decision making 4 inconsistency in networks of evidence based on randomized controlled trials. Med Decis Mak 33(5):641–656. https://doi.org/10.1177/0272989X12455847

    Article  Google Scholar 

  32. Higgins J, Jackson D, Barrett J, Lu G, Ades A, White I (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3(2):98–110. https://doi.org/10.1002/jrsm.1044

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  33. Valkenhoef G, Lu G, Brock B, Hillege H, Ades A, Welton NJ (2012) Automating network meta-analysis. Res Synth Methods 3(4):285–299. https://doi.org/10.1002/jrsm.1054

    Article  PubMed  Google Scholar 

  34. Development JR A Study comparing sirukumab (CNTO 136) monotherapy with adalimumab (HUMIRA®) monotherapy in the treatment of active rheumatoid arthritis (SIRROUND-H). Available from: https://clinicaltrials.gov/ct2/show/NCT02019472?term=NCT02019472&rank=1. NLM identifier: NCT01604343

  35. Trinquart L, Attiche N, Bafeta A, Porcher R, Ravaud P (2016) Uncertainty in treatment rankings: reanalysis of network meta-analyses of randomized trials uncertainty in treatment rankings from network meta-analyses. Ann Intern Med 164:666–673

    Article  PubMed  Google Scholar 

  36. Tarp S, Eric Furst D, Boers M, Luta G, Bliddal H, Tarp U, Heller Asmussen K, Brock B, Dossing A, Schjødt Jørgensen T (2017) Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology 56(3):417–425. https://doi.org/10.1093/rheumatology/kew442

    PubMed  Google Scholar 

  37. Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6(10):a016295. https://doi.org/10.1101/cshperspect.a016295

    Article  PubMed  PubMed Central  Google Scholar 

  38. Mueller RB, Graninger W, Sidiropoulos P, Goger C, von Kempis J (2017) Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study. Clin Rheumatol 36:2187–2192

    Article  PubMed  Google Scholar 

  39. Kishimoto T (2006) Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 8(Suppl 2):S2. https://doi.org/10.1186/ar1916

    Article  PubMed  PubMed Central  Google Scholar 

  40. Schmitz S, Adams R, Walsh CD, Barry M, FitzGerald O (2011) A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis 2011-200228

Download references

Acknowledgements

This study was supported in part by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (HI15C2958).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Young Ho Lee.

Ethics declarations

Disclosures

None.

Electronic supplementary material

ESM 1

(XLSX 60 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bae, SC., Lee, Y.H. Comparison of the efficacy and tolerability of tocilizumab, sarilumab, and sirukumab in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Clin Rheumatol 37, 1471–1479 (2018). https://doi.org/10.1007/s10067-018-4006-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-018-4006-5

Keywords

  • IL-6, biologics
  • Network meta-analysis
  • Rheumatoid arthritis